During the recent session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 0.82 million, with the beta value of the company hitting 0.58. At the last check today, the stock’s price was $1.08, reflecting an intraday gain of 12.38% or $0.12. The 52-week high for the NKTR share is $1.93, that puts it down -78.7 from that peak though still a striking 55.56% gain since the share price plummeted to a 52-week low of $0.48. The company’s market capitalization is $199.21M, and the average intraday trading volume over the past 10 days was 1.21 million shares, and the average trade volume was 1.74 million shares over the past three months.
Nektar Therapeutics (NKTR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.50. NKTR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.18.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Nektar Therapeutics (NKTR) registered a 12.38% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 12.38% in intraday trading to $1.08, hitting a weekly high. The stock’s 5-day price performance is 13.54%, and it has moved by 0.93% in 30 days. Based on these gigs, the overall price performance for the year is 93.90%. The short interest in Nektar Therapeutics (NASDAQ:NKTR) is 4.4 million shares and it means that shorts have 1.92 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.5, which implies an increase of 94.16% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $24 respectively. As a result, NKTR is trading at a discount of -2122.22% off the target high and -455.56% off the low.
Nektar Therapeutics (NKTR) estimates and forecasts
Statistics show that Nektar Therapeutics has outperformed its competitors in share price, compared to the industry in which it operates. Nektar Therapeutics (NKTR) shares have gone down -16.28% during the last six months, with a year-to-date growth rate more than the industry average at 51.03% against 16.60. In the rating firms’ projections, revenue will increase 19.08% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 38.04M as predicted by 8 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 23.72M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 23.89M and 21.64M respectively. In this case, analysts expect current quarter sales to grow by 59.28% and then jump by 9.62% in the coming quarter.
While earnings are projected to return 51.45% in 2025, the next five years will return -7.30% per annum.
NKTR Dividends
Nektar Therapeutics is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Nektar Therapeutics insiders own 1.30% of total outstanding shares while institutional holders control 76.59%, with the float percentage being 77.60%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 175.0 institutions own stock in it. As of 2024-06-30, the company held over 17.88 million shares (or 9.1789% of all shares), a total value of $22.17 million in shares.
The next largest institutional holding, with 15.16 million shares, is of BLACKROCK INC.’s that is approximately 7.7823% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $18.79 million.
